Immunoglobulin A nephropathy
Drug research and approvals for immunoglobulin A nephropathy: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 99 studies of immunoglobulin A nephropathy are recruiting on ClinicalTrials.gov, Health Canada has authorized 11 drug trials for it since 2013, FDA has 4 approved and 3 open orphan designations naming it, and the EU has 2 authorised medicines for it.
- Recruiting worldwide: 99
- Trials authorized in Canada: 11
- FDA orphan approvals: 4
- EU medicines: 2
- Pediatric Longitudinal Glomerular Disease: a PNRC Multi-Institutional Cohort StudyNCT07931170 · Not reported · Pediatric Nephrology Research Consortium · starts Oct 1, 2026
- Prospective Study of Cadonilimab With Lenvatinib in Renal Cell CarcinomaNCT07909265 · Phase 2 · Cancer Institute and Hospital, Chinese Academy of Medical Sciences · starts Apr 1, 2025
- A Phase 3 Blinded Study of JADE101 in Participants With Immunoglobulin A NephropathyNCT07902817 · Phase 3 · Jade Biosciences, Inc. · starts Dec 1, 2026
- A Phase 3b Study of Participant Experience on Povetacicept Administered Via Autoinjector as Compared to Sibeprenlimab…NCT07890909 · Phase 3 · Vertex Pharmaceuticals Incorporated · starts Nov 13, 2026
- Safety and Efficacy Study in Adults With Advanced Solid Tumors Receiving REGN13089-M404-M2980, an Antibody-drug…NCT07863024 · Phase 1 / Phase 2 · Regeneron Pharmaceuticals · starts Oct 28, 2026
- A Study of the Efficacy and Safety of Zigakibart + Atrasentan in Adult Patients With Primary IgA NephropathyNCT07850752 · Phase 3 · Novartis Pharmaceuticals · starts Nov 11, 2026
- To Assess the Efficacy and Safety of Utilizing Galactose-deficient IgA1 Biomarker Changes to Guide Pathogenic…NCT07822100 · Not applicable · Hong Zhang · starts Aug 24, 2026
- A Study of Clazakizumab (LY5724886) in Adults With Elevated hsCRP and at Increased Risk for Cardiovascular EventNCT07783802 · Phase 2 · Eli Lilly and Company · starts Aug 27, 2026
- A Study to Evaluate the Effect of ARGX-121 on the Change in Proteinuria in Adult Participants With IgANNCT07773727 · Phase 2 · argenx · starts Nov 5, 2026
How its trials ended
184 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 41 whose ending is known, 41% met their primary endpoint, 7% missed it and 51% stopped early.
- Ongoing6636%
- Completed, result not reported4927%
- Status unknown2815%
- Met its primary endpoint179%
- Stopped: other or unclear84%
- Stopped: sponsor or business decision74%
- Stopped: enrollment or feasibility42%
- Missed its primary endpoint32%
- Stopped: lack of efficacy21%
| Oct 14, 2026 | A single-arm, multicenter, phase III study to assess efficacy, pharmacokinetics, safety and tolerability of zigakibart in pediatric patients with primary…Zigakibart (FUB523) | Novartis Pharmaceuticals | Pending |
| Aug 28, 2026 | A phase 3, open-label, multicenter study to evaluate the pharmacokinetics, pharmacodynamics, efficacy, and safety of ravulizumab in pediatric participantsUltomiris [ravulizumab (ALXN1210)] | AstraZeneca Pharmaceuticals | Pending |
| Dec 17, 2024 | A phase 2b, multicenter, open-label, single-arm trial to evaluate the impact of sibeprenlimab on kidney histopathology through repeat kidney biopsies in…Sibeprenlimab (VIS649) | Otsuka Holdings | Ongoing |
| Aug 20, 2024 | A phase 3, randomized, double-blind, placebo-controlled study of povetacicept in adults with immunoglobulin A nephropathy (RAINIER)Povetacicept injection | Alpine Immune Sciences | Ongoing |
| Mar 12, 2024 | A phase 3, double-blind, randomized, adaptive design study to evaluate the efficacy and safety of ravulizumab in adult participants with immunoglobulin A…Ravulizumab (ALXN1210) | AstraZeneca Pharmaceuticals | Ongoing |
| Jun 21, 2022 | A phase 3, multicenter, randomized, doubleblind, placebo-controlled trial to evaluate the efficacy and safety of sibeprenlimab administered subcutaneously in…Sibeprenlimab (VIS649) | Otsuka Holdings | Closed |
| Jun 16, 2022 | A phase 2/3, multicenter, open label trial to evaluate the long term safety, tolerability, and efficacy of sibeprenlimab administered subcutaneously in…Sibeprenlimab (VIS649) | Otsuka Holdings | Ongoing |
| Mar 10, 2020 | A multicenter, randomized, double-blind, placebo-controlled, multiple dose study to evaluate the efficacy and safety of VIS649 in participants with…VIS649 | Visterra, Inc | Ongoing |
| Feb 22, 2019 | A phase 2, randomized, double-blind, placebo-controlled study of cemdisiran in adult patients with iga nephropathyCemdisiran (ALN-CC5) | Alnylam Pharmaceuticals | Closed |
| May 18, 2018 | A randomized, double-blind, placebo-controlled, phase 3 study of the safety and efficacy of OMS721 in patients with immunoglobulin A (IGA) nephropathy…OMS721 | Omeros | Ongoing |
| Sep 5, 2024 | FilspariTo slow kidney function decline in adults with primary immunoglobulin A nephropathy (IgAN) who are at risk for disease progression | Travere Therapeutics, Inc. | Approved |
| Dec 20, 2023 | TarpeyoTo reduce the loss of kidney function in adults with primary immunoglobulin A nephropathy (IgAN) who are at risk for disease progression | Calliditas Therapeutics AB | Approved |
| Feb 17, 2023 | FilspariTo reduce proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk of rapid disease progression, generally a urine… | Travere Therapeutics, Inc. | Approved |
| Dec 15, 2021 | TarpeyoTo reduce proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk of rapid disease progression, generally a urine… | Calliditas Therapeutics AB | Approved |
| Aug 7, 2017 | BlisibimodTreatment of patients with immunoglobulin A nephropathy | Anthera Pharmaceuticals, Inc. | Designated |
| Aug 3, 2017 | Human monoclonal antibody inhibitor of mannan binding…Treatment of immunoglobulin A nephropathy (IgAN) | Omeros Corporation | Designated |
| Apr 18, 2011 | Recombinant IgA protease of bacterium Heamophilus influenzaeTreatment of immunoglobulin A nephropathy (IgAN, Berger's disease). | Shire Human Genetics Therapies | Designated |
| Apr 19, 2024 | FilspariSparsentan · orphan | Vifor France | EMA ↗ |
| Jul 15, 2022 | KinpeygoBudesonide · orphan | Stada Arzneimittel AG | EMA ↗ |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA